CIZZLE BIOTECHNOLOGY HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 GBX | 0.00% |
|
+1.49% | -12.82% |
| 04-30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| 04-30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.09M 9.04M 12.35M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -1M -1.27M -1.74M | EV / Sales 2022 | - |
| Net cash position 2022 | 478K 609K 832K | Net cash position 2023 | 1.56M 1.98M 2.71M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-4.04
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.88% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +1.49% | ||
| Current month | +3.03% | ||
| 3 months | -26.09% | ||
| 6 months | -17.07% | ||
| Current year | -12.82% |
1 week
1.60
1.75
1 month
1.571.85
Current year
1.573.38
1 year
1.573.38
3 years
1.308.25
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 21-05-13 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
John Treacy
BRD | Director/Board Member | 42 | 19-01-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 1.7 | 0.00% | 168,144 |
| 24-05-23 | 1.7 | +1.49% | 438,742 |
| 24-05-22 | 1.675 | 0.00% | 222,236 |
| 24-05-21 | 1.675 | 0.00% | 87,584 |
| 24-05-20 | 1.675 | 0.00% | 153,570 |
Delayed Quote London S.E., May 24, 2024 at 11:35 am
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.82% | 8.59M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- PSL Stock
